Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SALT LAKE CITY, Dec. 28, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St. Francis Hotel in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, GeneSight, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (908) 285-0248 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
